We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris (OREA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05131373
Recruitment Status : Recruiting
First Posted : November 23, 2021
Last Update Posted : July 11, 2022
Sponsor:
Information provided by (Responsible Party):
Origimm Biotechnology GmbH

Brief Summary:
This trial investigates the safety and tolerability of three different doses of a C. acnes vaccine (ORI-A-ce001) in subjects with acne vulgaris.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: ORG101 - Experimental 1 Drug: ORG101PL - Placebo 1 Phase 1

Detailed Description:

Acne vulgaris, or acne, is one of the most prevalent diseases worldwide, with skin conditions being one of the top causes of years lived with disability and non-fatal disease burden. Despite being one of the most prevalent diseases worldwide, the most widely used treatments in acne have changed little in the past 30 years. To date there is still no effective treatment that can prevent and cure this disease. The currently available acne therapies have been discovered several decades ago, and almost no progress was made in developments of novel, breakthrough treatment approaches.

The present randomized, placebo-controlled, dose escalation, Phase 1 trial (ORI-101-PAC) is intended to investigate the safety, tolerability and immunogenicity of an acne vulgaris vaccine (ORI-A-ce001) at three different dose levels in subjects aged ≥18 years suffering from moderate facial acne vulgaris who are otherwise healthy. The present study will also generate preliminary data on efficacy (inflammatory and non-inflammatory acne lesion counts, acne severity), immunogenicity and functionality of the vaccine, as well as a possible impact on skin microbiome composition. Control groups receiving placebo are included. Data from this trial will be used to inform the design of future studies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Sequential cohorts (dose escalation)
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: double-blind
Primary Purpose: Treatment
Official Title: A Phase I, Multi-center, Double-blind, Randomized, Dose Escalating, Parallel Group, Placebo-controlled Safety, Tolerability and Immunogenicity Study of ORI-A-ce001 for the Treatment of Facial Acne Vulgaris
Actual Study Start Date : September 28, 2021
Estimated Primary Completion Date : June 8, 2023
Estimated Study Completion Date : June 8, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Experimental: Experimental 1
C. acnes vaccine in adjuvanted formulation will be administered in double-blind fashion in 3 single increasing doses given i.m.
Drug: ORG101 - Experimental 1
C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals

Placebo Comparator: Placebo 1
Placebo in adjuvanted formulation will be administered in double-blind fashion in single i.m. injections
Drug: ORG101PL - Placebo 1
Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals




Primary Outcome Measures :
  1. Incidence of solicited and unsolicited local and/or systemic adverse events (AEs) [ Time Frame: 7 days following each vaccination ]
    Number of participants with AEs as assessed by electronic diary (eDiary) and/or PI assessment, and compared to placebo

  2. Incidence of AEs and serious adverse events (SAEs) [ Time Frame: through study completion, an average of 9 months ]
    Incidence of AEs and SAEs

  3. Number of participants with AEs or SAEs as assessed by physical examination [ Time Frame: through study completion, an average of 9 months ]
    Number of participants with AEs or SAEs as assessed by physical examination, vital signs, local skin responses, as assessed by treatment arm (vaccine and placebo)

  4. Change from the baseline in laboratory data [ Time Frame: through study completion, an average of 9 months ]
    Clinically significant change from the baseline in laboratory data as compared to placebo

  5. Change from the baseline in vital signs [ Time Frame: through study completion, an average of 9 months ]
    Clinically significant change from the baseline in vital signs as compared to placebo

  6. Change from the baseline in ECG [ Time Frame: Weeks 0 and 36 ]
    Clinically significant change from the baseline in electrocardiogram (ECG) as compared to placebo

  7. Change from the baseline in physical examination [ Time Frame: through study completion, an average of 9 months ]
    Clinically significant change from the baseline in physical examination, as compared to placebo


Secondary Outcome Measures :
  1. Immunogenicity assessment [ Time Frame: Weeks 0, 4, 8, 12, 16, 24 and 36 ]
    The amount of vaccine-antigen-specific serum antibody titers (IgG), measured by ELISA, compared to placebo and compared among different treatment groups

  2. Change in inflammatory lesion counts [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36 ]
    Absolute and percentage change from Baseline in the number of inflammatory acne lesions

  3. Change in non-inflammatory lesion counts [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36 ]
    Absolute and percentage change from Baseline in the number of non-inflammatory acne lesions

  4. Investigator's global assessment (IGA) - change from Baseline [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36 ]
    Absolute change in IGA score from Baseline [scores: 0-4; 0=clear, 4=severe]

  5. Investigator's global assessment (IGA) - percentage of subjects with improvement [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36 ]
    Percentage of subjects with at least one-grade improvement in their Baseline IGA score (assessment of mild, clear or almost clear) [scores: 0-4; 0=clear, 4=severe]

  6. Assessment of subjects' treatment acceptability [ Time Frame: Week 16 ]
    Treatment acceptability, as assessed by the pre-defined questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subject aged ≥18 years at the time of informed consent signature
  • Female subjects of childbearing potential must have a negative serum or urine pregnancy test at Screening and before vaccination and must be willing to practice a highly effective method of contraception during the study
  • Subject with a clinical diagnosis of moderate facial acne vulgaris (grade 3 on a 5-grade IGA scale) at Baseline Visit
  • Subject must have a maximum of 40 non-inflammatory acne lesions (open and closed comedones) and between a minimum of 20 and a maximum of 70 inflammatory acne lesions (papules and pustules) and a maximum of 1 nodulocystic lesion (nodules and cysts) on the face (e.g., forehead, nose, cheeks, chin, upper lip) at Baseline Visit
  • Negative Covid test at Baseline Visit

Exclusion Criteria:

  • Subject who is pregnant, lactating or is planning a pregnancy during the study period
  • Subject who has active nodulocystic acne, acne conglobata, acne fulminans, secondary acne or other forms of acne
  • Subject who has more than one facial nodules/cysts (where nodule/cyst is defined as an inflammatory lesion greater than or equal to 0.5 cm in size with or without cystic changes)
  • Subject who has any skin pathology or condition that, in the Investigator's opinion, could interfere with the evaluation of the Investigational Medicinal Product (IMP) or requires use of interfering topical, systemic, or surgical therapy
  • Subject with excessive facial hair, facial skin disorders, skin reactions that may interfere with the study assessments in the Investigator's opinion or skin infection
  • History of Guillain-Barré-Syndrome
  • Subject who has used any acne-affecting treatment without an appropriate washout period
  • Subject who receives active or passive vaccination within 30 days prior to Baseline Visit Initiation or change of hormonal contraceptive use within 12 weeks prior to Screening Visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05131373


Contacts
Layout table for location contacts
Contact: Ira G Federspiel, PhD +436763699216 ira.federspiel@sanofi.com

Locations
Layout table for location information
Germany
Universitäts-Hautklinik Tübingen Recruiting
Tübingen, Baden-Wuerttemberg, Germany, 72074
Contact: Matthias Hahn, Dr. med.         
Universitätsklinikum Frankfurt Recruiting
Frankfurt, Hesse, Germany, 60590
Contact: Andreas Pinter, Dr. med.         
Fachklinik Bad Bentheim Recruiting
Bad Bentheim, North Rhine-Westphalia, Germany, 48455
Contact: Athanasios Tsianakas, PD Dr.med.         
Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) Recruiting
Bochum, North Rhine-Westphalia, Germany, 44791
Contact: Falk Bechara, Prof.Dr.med.         
CentroDerm Recruiting
Wuppertal, North Rhine-Westphalia, Germany, 42287
Contact: Thomas Dirschka, Prof.Dr.med.         
UKSH, Campus Lübeck Recruiting
Lübeck, Schleswig-Holstein, Germany, 23538
Contact: Diamant Thaci, Prof.Dr.med.         
Sponsors and Collaborators
Origimm Biotechnology GmbH
Investigators
Layout table for investigator information
Study Director: Zrinka Ivezic-Schoenfeld, PhD Origimm Biotechnology GmbH
Additional Information:
Layout table for additonal information
Responsible Party: Origimm Biotechnology GmbH
ClinicalTrials.gov Identifier: NCT05131373    
Other Study ID Numbers: ORI-101-PAC
First Posted: November 23, 2021    Key Record Dates
Last Update Posted: July 11, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Origimm Biotechnology GmbH:
acne vulgaris
C. acnes
vaccine
dose escalation
first in human
FIH
skin microbiome
placebo
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases